NEJM publishes phase III study of nirogacestat in adults with progressing desmoid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Data from the phase III DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, were published in The New England Journal of Medicine. Results from this study were previously presented at the European Society for Medical Oncology Congress in September 2022.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login